In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Abraham Pedroza-TorresCátedra SECIHTI-Clínica de Cáncer Hereditario, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.
Noemí Baranda-AvilaLaboratory of mRNA and Cancer, Unit of Biomedical Research on Cancer, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.
Jorge L RamírezLaboratory of mRNA and Cancer, Unit of Biomedical Research on Cancer, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.
Maricruz GonzálezLaboratory of mRNA and Cancer, Unit of Biomedical Research on Cancer, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.
Pamela A GonzálezLaboratory of mRNA and Cancer, Unit of Biomedical Research on Cancer, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.
Blanca L TorresLaboratory of mRNA and Cancer, Unit of Biomedical Research on Cancer, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.ORCID 0009-0006-2669-4364 Miguel A Jiménez-RíosDepartment of Oncologic Urology, National Institute of Cancer (INCan), Mexico City 14080, Mexico.
Alfonso Méndez-TenorioLaboratory of Biotechnology and Genomic Bioinformatics, National School of Sciences, National Polytechnic Institute (Instituto Politécnico Nacional), Mexico City 07840, Mexico.ORCID 0000-0003-1871-4311 Rosa María Álvarez-GómezClínica de Cáncer Hereditario, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.ORCID 0000-0002-5458-7201 Greco HernándezLaboratory of mRNA and Cancer, Unit of Biomedical Research on Cancer, National Institute of Cancer (Instituto Nacional de Cancerología, INCan), Mexico City 14080, Mexico.ORCID 0000-0002-5318-4443 Funding
Instituto Nacional de Cancerología and SECIHTI (former CONACyT) 273116
6 · The paper itselfAbstract
Prostate cancer (PCa) is the second most frequent tumor and the fifth leading cause of cancer-related death in men worldwide. PCa shows the largest clinical disparities across Asian, Caucasian, and African descendants among all cancer types, proving that the ethnic genetic background plays a significant role in PCa.
Indexed as
High-Throughput Nucleotide SequencingMutationProstatic NeoplasmsReceptors, AndrogenAgedHepatocyte Nuclear Factor 3-alphaHumansMaleMiddle AgedNuclear ProteinsRepressor ProteinsTOR Serine-Threonine KinasesTumor Suppressor Protein p53AR protein, humanFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaMTOR protein, humanNuclear ProteinsReceptors, AndrogenRepressor ProteinsSPOP protein, humanTOR Serine-Threonine KinasesTP53 protein, humanTumor Suppressor Protein p53Androgen ReceptorFOXA1prostate cancerSPOPTP53
Identifiers
PMID41009328
PMCPMC12469278
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390